Rhophylac Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of prenatal care services, adoption of routine rh immunoglobulin administration, improvements in blood product safety, growth in hospital-based obstetric services, increasing access to maternal healthcare.

The growth in the forecast period can be attributed to rising demand for preventive maternal therapies, expansion of high-risk pregnancy management programs, increasing focus on reducing hemolytic disease incidence, growth of specialty plasma therapies, strengthening of transfusion safety standards. Major trends in the forecast period include increasing use of prophylactic anti-d therapies, rising awareness of rh incompatibility risks, expansion of maternal screening programs, improved plasma-derived product safety, enhanced focus on obstetric care protocols.

The rising awareness of blood safety is expected to drive growth in the Rhophylac market going forward. Blood safety encompasses practices and measures aimed at preventing contamination and transmission of infections, ensuring the safe collection, handling, and transfusion of blood and blood products. Increased public health campaigns, advancements in blood screening technologies, stricter regulatory standards, global health crises, higher incidence of bloodborne diseases, and enhanced medical training have contributed to this growing awareness. Rhophylac supports blood safety by preventing Rh incompatibility in pregnant women, ensuring proper blood management, and reducing the risk of hemolytic disease of the newborn. For example, in August 2023, the Royal College of Pathologists, a UK-based organization, reported that nearly 2 million blood components were issued and transfused in England annually, costing over £300 million ($390.69 million). Therefore, rising awareness of blood safety is driving the growth of the Rhophylac market.

Increasing healthcare expenditure is also expected to propel the Rhophylac market. Healthcare expenditure refers to the total spending on medical services, products, and infrastructure over a specific period. Growth in healthcare expenditure is driven by aging populations, advancements in medical technologies, and higher demand for healthcare services. Rhophylac contributes to cost-effective care by preventing Rh incompatibility-related complications in pregnancy, thereby avoiding expensive treatments for hemolytic disease of the newborn. For instance, in July 2024, Statistics Austria reported that Austria’s healthcare expenditure reached $56.47 billion (€52.28 billion) in 2023, representing 10.9% of the country’s GDP and a 4.8% increase from 2022. Therefore, rising healthcare expenditure is supporting the growth of the Rhophylac market.

The growing number of organ transplants is expected to further drive the Rhophylac market. Organ transplants involve replacing a failing or damaged organ with a healthy donor organ to improve or save a patient’s life. Advances in medical technology, improved surgical techniques, better post-transplant care, increased donor awareness, and rising prevalence of chronic diseases such as kidney failure, heart disease, and liver cirrhosis have contributed to the increase in transplant procedures. Rhophylac is used in these settings to prevent immune rejection and alloimmunization by providing passive immunization with Rh immunoglobulin, reducing sensitization to foreign antigens. For example, in January 2025, the Organ Procurement and Transplantation Network reported 27,759 kidney transplants in 2024, a 1.6% increase from 2023, while heart transplants remained relatively stable at 4,572 procedures compared to 4,545 in 2023. Therefore, the growing number of organ transplants is driving the Rhophylac market.

Major companies operating in the rhophylac market are CSL Behring AG.

North America was the largest region in the rhophylac market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rhophylac market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rhophylac market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are affecting the rhophylac market by increasing costs of plasma collection materials, fractionation equipment, sterile packaging, and cold chain logistics used in immunoglobulin production. Europe and North America are most impacted due to reliance on cross-border plasma sourcing, while emerging regions face higher import costs for finished products. These tariffs are adding pricing pressure to hospitals and maternal care providers. At the same time, they are supporting domestic plasma collection initiatives, regional manufacturing investments, and improved supply chain resilience for plasma-derived therapies.

The rhophylac market research report is one of a series of new reports that provides rhophylac market statistics, including rhophylac industry global market size, regional shares, competitors with a rhophylac market share, detailed rhophylac market segments, market trends and opportunities, and any further data you may need to thrive in the rhophylac industry. This rhophylac market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rhophylac is a human anti-D immunoglobulin used to prevent Rh sensitization in Rh-negative individuals exposed to Rh-positive red blood cells. It is commonly given during pregnancy, after delivery, or following blood transfusions to prevent complications such as hemolytic disease of the newborn.

The primary indications for Rhophylac include suppression of Rh isoimmunization, management of incompatible transfusions, and treatment of immune thrombocytopenic purpura (ITP). Suppression of Rh isoimmunization involves administering Rh immunoglobulin to an Rh-negative mother to prevent the formation of antibodies against Rh-positive fetal blood cells, thereby reducing risks in future pregnancies. Rhophylac is administered via intravenous (IV) and intramuscular (IM) routes and is distributed through hospitals, clinics, and pharmacies. End users include pediatric, adult, and geriatric patients.

The rhophylac market consists of sales of injections, vials, pre-filled syringes, rh immunoglobulin products, and companion products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.